Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialByeong-Ho Park, David H. Kirn, Sung Yong Oh et al.|The Lancet Oncology|2008Cited by 522
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).Se Hoon Park, Won Ki Kang, Dae Young Zang et al.|Journal of Clinical Oncology|2019Cited by 79
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human studyYunlin Zhang, Marco Ruella, Ruchi P. Patel et al.|Molecular Cancer|2023Cited by 32